Drug Trial Radar · NCT05810116
Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain
Last checked: Nov 20, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
May 19, 2023
Primary completion
Dec 20, 2023
Study completion Dec 20, 2023
Sponsor
- Lead sponsor
- RDC Clinical Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Palmitoylethanolamide (PEA) compared to placebo on menstrual pain in otherwise healthy participants 18 years and over.
Conditions
- Menstrual Pain
Interventions
Levagen+Drug
Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
Microcrystalline celluloseDrug
Daily dose of 1-2 capsules (1 capsule containing 350mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in acute menstrual pain severity, analgesic effect via Numeric Rating Scale (NRS)Time frame: 4 menstrual pain events over a maximum of 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
RDC Clinical Pty Ltd
New Farm, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.